Chemomab director sells 2,304 ADS at ~$2.8
Chemomab Therapeutics Ltd. (CMMB) director Neil Harris Cohen reported both share sales and option awards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. (CMMB) director Neil Harris Cohen reported both share sales and option awards. He sold 1,000 American Depositary Shares at $2.80 on August 28, 2026 and 1,304 ADS at $2.85 on August 27, 2026. Cohen also reported multiple prior grants of stock options to purchase ADS, many of which are noted as fully vested and exercisable as of this report.
Insider Trade Summary
Net Seller: 2,304 shares
Net Sell
9 txns
Insider
Cohen Neil Harris
Role
Director
Sold
2,304 shs ($7K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | American Depositary Shares | 1,000 | $2.80 | $3K |
| Sale | American Depositary Shares | 1,304 | $2.85 | $4K |
| Grant/Award | Stock option (right to buy American Depositary Shares) | 5,172 | $0.00 | $0.00 |
| Grant/Award | Stock option (right to buy American Depositary Shares) F6 | 3,821 | $0.00 | $0.00 |
| Grant/Award | Stock option (right to buy American Depositary Shares) F5 | 2,520 | $0.00 | $0.00 |
| Grant/Award | Stock option (right to buy American Depositary Shares) F4 | 1,714 | $0.00 | $0.00 |
| Grant/Award | Stock option (right to buy American Depositary Shares) F3 | 1,705 | $0.00 | $0.00 |
| Grant/Award | Stock option (right to buy American Depositary Shares) F2 | 2,971 | $0.00 | $0.00 |
| Grant/Award | Stock option (right to buy American Depositary Shares) F1 | 172 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy American Depositary Shares) — 54,785 contracts (Direct);
American Depositary Shares — 33,000 shares (Direct)
Footnotes (6)
- F1. The options reported in this row were granted to the Reporting Person by the Issuer on July 16, 2020, and are fully vested and exercisable as of the date of this report.
- F2. The options reported in this row were granted to the Reporting Person by the Issuer on April 19, 2021, and are fully vested and exercisable as of the date of this report.
- F3. The options reported in this row were granted to the Reporting Person by the Issuer on March 7, 2022, and are fully vested and exercisable as of the date of this report.
- F4. The options reported in this row were granted to the Reporting Person by the Issuer on March 21, 2023, and are fully vested and exercisable as of the date of this report.
- F5. The options reported in this row were granted to the Reporting Person by the Issuer on March 18, 2024, and are fully vested and exercisable as of the date of this report.
- F6. The options reported in this row were granted to the Reporting Person by the Issuer on March 16, 2025, and are fully vested and exercisable as of the date of this report.
Key Figures
ADS sold: 1,000 shares at $2.80
ADS sold: 1,304 shares at $2.85
Stock options granted: 5,172 options at $2.14 exercise price
+5 more
8 metrics
ADS sold
1,000 shares at $2.80
Sale of American Depositary Shares on 2026-08-28
ADS sold
1,304 shares at $2.85
Sale of American Depositary Shares on 2026-08-27
Stock options granted
5,172 options at $2.14 exercise price
Grant on 2026-03-16, expiring 2036-03-16
Stock options granted
3,821 options at $6.16 exercise price
Grant on 2025-03-16, fully vested as of report date
Stock options granted
2,520 options at $2.96 exercise price
Grant on 2024-03-18, fully vested as of report date
Stock options granted
1,714 options at $6.48 exercise price
Grant on 2023-03-21, fully vested as of report date
Stock options granted
1,705 options at $14.12 exercise price
Grant on 2022-03-07, fully vested as of report date
Stock options granted
2,971 options at $109.04 exercise price
Grant on 2021-04-19, fully vested as of report date
Key Terms
American Depositary Shares, Stock option, exercise price, fully vested and exercisable, +1 more
5 terms
Stock option financial
"security_title": "Stock option (right to buy American Depositary Shares)""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "2.1400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested and exercisable financial
"are fully vested and exercisable as of the date of this report"
Rule 10b5-1 regulatory
"document-level Rule 10b5-1 checkbox"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did CMMB director Neil Harris Cohen report in this Form 4?
Neil Harris Cohen reported two sales of Chemomab ADS totaling 2,304 shares and multiple stock option grants covering ADS, several of which are described as fully vested and exercisable as of the date of the report.
What new stock option grant did Neil Harris Cohen receive for Chemomab (CMMB) ADS?
On March 16, 2026, Neil Harris Cohen was granted 5,172 stock options to buy Chemomab ADS at a $2.14 exercise price, expiring on March 16, 2036, with an exercise date shown as March 16, 2027.
Which Chemomab (CMMB) stock options held by Neil Harris Cohen are fully vested?
Footnotes state that option grants dated July 16, 2020, April 19, 2021, March 7, 2022, March 21, 2023, March 18, 2024, and March 16, 2025 are all fully vested and exercisable as of the date of this report.
Does this Chemomab (CMMB) Form 4 indicate trades under a Rule 10b5-1 plan?
The Form 4 data show the document-level Rule 10b5-1 checkbox as unchecked, and the footnotes do not mention any Rule 10b5-1 trading plan in connection with the reported transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
